



ZAP-1 CIP CON CIP

Amended Claims

1. [amended] A method for inhibiting metastasis of lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab, Fc and single chain immunoglobulins.

EXPRESS MAIL  
EK708046135US

Please amend the claims as follows:

Sub B1  
A1 1. [amended] A method for inhibiting metastasis of lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab, Fc and single chain immunoglobulins.

Please add the following new claims:

Sub B3  
22. [new] A method for treating lymphoma in a mammal which comprises subcutaneously administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab, Fc and single chain immunoglobulins.

23. [new] The method of claim 22 wherein the preparation is administered in a dosage range of 4-20 mg/kg of body weight.

A2 Sub B1  
24. [new] A method for treating lymphoma in a mammal which comprises intracavitarily administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab, Fc and single chain immunoglobulins.

25. [new] A method for treating lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of F(ab')<sub>2</sub>, Fab', Fab, Fc and single chain immunoglobulins, wherein the method further comprises subjecting the mammal to at least one other treatment modality selected from the group consisting of immunotherapy,

radiation therapy and surgery, and wherein the other treatment modality is administered prior to, during or after the administration of IVIG.

26. [new] A method for treating Hodgkin's lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of  $F(ab')_2$ , Fab', Fab, Fc and single chain immunoglobulins, wherein the method further comprises subjecting the mammal to at least one other treatment modality.

27. [new] The method according to claim 26 wherein the other treatment modality is selected from the group consisting of chemotherapy, immunotherapy, radiation therapy and surgery, and wherein the other treatment modality is administered prior to, during or after the administration of IVIG.

28. [new] A method for treating lymphoma in a mammal which comprises administering to the mammal a preparation of IVIG or fragments thereof selected from the group consisting of  $F(ab')_2$ , Fab', Fab, Fc and single chain immunoglobulins, wherein the method further comprises surgically removing the lymphoma prior to, during or after the administration of the preparation of IVIG or fragments thereof.

29. [new] A method for treating lymphoma in a mammal which comprises administering to the mammal a preparation of fragments of IVIG selected from the group consisting of  $F(ab')_2$ , Fab', Fab, Fc and single chain immunoglobulins.



### Amendments

Applicants have canceled, without prejudice, claims 12 - 21. Applicants have amended claim 1. Applicants have added new claims 22-29.

Applicants have amended the claims (i.e., claim 1) that recite fragments of IVIG to list species of IVIG fragments. Support for this amendment is found, e.g., at specification page 4, lines 19-21.

Applicants have added new claim 22 to recite subject matter formerly included in claim 16, i.e., the subcutaneous administration of IVIG for the treatment of lymphoma. Applicants have added new claim 23 to recite a specific dosage range for the subcutaneous administration of IVIG of claim 22. Support for claim 23 can be found in the specification at page 6, lines 23-26. Applicants have added new claim 24 to recite subject matter formerly included in claim 15, i.e., the intracavitary administration of IVIG for the treatment of lymphoma. Applicants have added new claim 25-27 to recite subject matter formerly included in claims 19 and 20, i.e., the treatment of lymphoma, or specifically Hodgkin's lymphoma, with IVIG or fragments thereof in addition to another treatment modality. Applicants have added new claim 28 to recite subject matter formerly included in claim 21, i.e., the treatment of lymphoma wherein the lymphoma is surgically removed prior to, during or after the administration of a preparation of IVIG or fragments thereof. Applicants have added new claim 29 directed to treatment of lymphoma with specific fragments of IVIG.

As none of these amendments adds new matter, applicants respectfully request that the amendments be entered.